Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20561794 | 0.83 | KMT2A (0.41) | MAPTPOLBNPC1RAB9AMEN1 | |
| SCHEMBL22607861 | 0.80 | TRPM8 (0.43) | PKMMAPTPOLBRAB9ATRPM8 | |
| SCHEMBL25078271 | 0.79 | TSHR (0.49) | NPSR1PKMMAPTPOLBNPC1 | |
| SCHEMBL2779791 | 0.79 | TRPM8 (0.45) | PKMMAPTPOLBTRPM8MEN1 | |
| SCHEMBL8083280 | 0.78 | KDM4E (0.44) | PKMMAPTTRPM8LMNASMN1; SMN2 | |
| SCHEMBL2684237 | 0.77 | PKM (0.43) | NPSR1PKMMAPTPOLBNPC1 | |
| SCHEMBL31549227 | 0.75 | MAPK1 (0.45) | PKMMAPTNPC1RAB9ATRPM8 | |
| SCHEMBL7961734 | 0.74 | ADAMTS5 (0.40) | MAPTPOLBNPC1RXFP1MEN1 | |
| SCHEMBL15269918 | 0.74 | PKM (0.51) | NPSR1PKMMAPTPOLBNPC1 | |
| SCHEMBL15532895 | 0.74 | PKM (0.39) | PKMMAPTTRPM8MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667630-B2 | Nitrogen-containing 6-membered cyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-06-06 | — | — | US | disclosed |
| US-11667630-B2 | Nitrogen-containing 6-membered cyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-06-06 | — | — | US | disclosed |
| US-11667630-B2 | Nitrogen-containing 6-membered cyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-06-06 | — | — | US | disclosed |
| CN-111511736-B | Nitrogen-containing 6-membered ring compound | 旭化成制药株式会社 | 2023-03-24 | — | — | CN | disclosed |
| EP-3733665-B1 | 2-OXO-1,3,4-THIADIAZINAN-3-YL MOIETY CONTAINING COMPOUNDS WITH EP4 RECEPTOR AGONIST ACTIVITY | ASAHI KASEI PHARMA CORP (JP) | 2022-09-28 | — | — | EP | disclosed |
| US-20210188837-A1 | NITROGEN-CONTAINING 6-MEMBERED CYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2021-06-24 | — | — | US | disclosed |
| US-20210188837-A1 | NITROGEN-CONTAINING 6-MEMBERED CYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2021-06-24 | — | — | US | disclosed |
| US-10988468-B2 | Nitrogen-containing 6-membered cyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| US-10988468-B2 | Nitrogen-containing 6-membered cyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| US-20200347046-A1 | NITROGEN-CONTAINING 6-MEMBERED CYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2020-11-05 | — | — | US | disclosed |
| US-20200347046-A1 | NITROGEN-CONTAINING 6-MEMBERED CYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2020-11-05 | — | — | US | disclosed |
| EP-3733665-A1 | NITROGEN-CONTAINING SIX-MEMBERED RING COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2020-11-04 | — | — | EP | disclosed |
| EP-3733665-A1 | NITROGEN-CONTAINING SIX-MEMBERED RING COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2020-11-04 | — | — | EP | disclosed |
| CN-111511736-A | Nitrogen-containing 6-membered ring compound | 旭化成制药株式会社 | 2020-08-07 | — | — | CN | disclosed |
| US-7531655-B2 | Large conductance calcium-activated K channel opener | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| US-7531655-B2 | Large conductance calcium-activated K channel opener | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| US-6184245-B1 | Cyclic ketone derivatives and their medical applications | TORAY INDUSTRIES INC. (JP) | 2001-02-06 | — | — | US | disclosed |
| EP-0962456-A1 | CYCLIC KETONE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1999-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188837-A1 | NITROGEN-CONTAINING 6-MEMBERED CYCLIC COMPOUND | PTGER4, EPB41, BMP4 | NPSR1 127/4885PKM 3900/4885MAPT 4727/4885 |
| US-10988468-B2 | Nitrogen-containing 6-membered cyclic compound | PTGER4, EPB41, BMP4 | NPSR1 127/4885PKM 3900/4885MAPT 4727/4885 |
| US-11667630-B2 | Nitrogen-containing 6-membered cyclic compound | PTGER4, EPB41, BMP4 | NPSR1 127/4885PKM 3900/4885MAPT 4727/4885 |
| US-20200347046-A1 | NITROGEN-CONTAINING 6-MEMBERED CYCLIC COMPOUND | PTGER4, EPB41, BMP4 | NPSR1 127/4885PKM 3900/4885MAPT 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.